The only examples are lenalidomide for low-risk MDS with del(5q), erythropoiesis-stimulating agents (ESA) for patients with only modestly elevated levels of endogenous erythropoietin, and luspatercept for lower-risk MDS with ring sideroblasts and/or SF3B1 mutation. This evidence concerns the gene EPO and myelodysplastic syndrome.